Luseogliflozin: Phase III data

The double-blind, Japanese Phase III Study-1 in 158 Type II diabetics showed that once-daily 2.5 mg oral luseogliflozin met the primary endpoint of reducing HabA1c from baseline to week 24 vs. placebo...